This attack does 40 damage to 1 of your opponent's Pokémon. (Don't apply Weakness and Resistance for Benched Pokémon.) Switch this Pokémon with 1 of your Benched Pokémon.
If your opponent's Active Pokémon already has any damage counters on it, this attack does 100 more damage.
Crown Zenith was released in 2023. Crown Zenith is grouped under the Sword & Shield era.
With 160 listed cards, this is a mid-size set by modern TCG standards. As of 2026, the set is 3 years old and sits in a modern-era collecting window.
In the Crown Zenith checklist, Luxray occupies position #43 as a Rare card.
In 2023, Crown Zenith introduced this print of Luxray. The printed flavor text states: "Luxray's ability to see through objects comes in handy when it's scouting for danger." Core profile: Its card type is Pokémon.
The rarity label is Rare. Printed HP is 150.
Energy typing is Lightning. This card evolves from Luxio.
Attack line includes "Electrostep" and "Scar Strikes". It is weak to Fighting type energy.
Latest market snapshots place Luxray in Crown Zenith at roughly $0.15. Its 7-day movement is largely flat at 0.0%.
That is close to the 30-day average of $0.15. The 90-day window shows a floor near $0.10 and a peak around $0.18 (53% total spread), which maps to high-volatility movement.
The listed rarity for this print is Rare.
Collectors tracking Luxray often benchmark it against other Luxray cards. This comparison sample includes 6 alternatives across 6 sets.
In this sample, pricing ranges between $0.18 and $11.78 (6444% total span). Relative to the alternative average ($2.22), this card is -93%.
Notable alternatives include Luxray #46 (BREAKpoint) at $0.31, Luxray #34 (Flashfire) at $0.55, Luxray #SWSH023 (SWSH Black Star Promos) at $11.78, and Luxray #51 (Brilliant Stars) at $0.18.
Pricing context for collectors: Over the last 7 days, prices have remained stable at 0.0%, indicating a consolidation phase over sudden breakouts. With a 53% 90-day spread ($0.10-$0.18), this card currently tracks as high-volatility.
Relative to the 30-day baseline ($0.15), pricing is near equilibrium. Top-grade copies show substantial separation from raw: PSA 10 is pricing +25233% above the current raw benchmark.
PSA 9 is currently around $9.00, while PSA 10 is $38.00.
